Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) on January 21 and set a price target of ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

Fintel reports that on January 21, 2025, RBC Capital downgraded their outlook for CF Industries Holdings (NYSE:CF) from ...

Each year, RBC supports thousands of students from different educational backgrounds in exploring various career paths within ...

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...

Investing.com -- RBC Capital Markets has downgraded both Anglo American (JO: AGLJ) plc and Antofagasta (LON: ANTO) plc to ...

In the last two years, it’s happened for the fifth time. The S&P 500 was up 26% in 2023 and 25% in 2024, for the best ...

RBC Capital Markets raised its recommendation on KB Home (NYSE:KBH) and Lennar (NYSE:LEN), considering the homebuilders' ...

A small change in BBVA’s takeover offer for Banco Sabadell SA announced Thursday seems to be a correction of a previous ...